Novartis’ Cosentyx Wins CHMP Backing for Adolescents
The CHMP backed Cosentyx for hidradenitis suppurativa in patients aged 12 and older.
Related stories
China to Add JW Therapeutics’ CAR-T Therapy to State Insurance
China’s National Healthcare Security Administration says JW Therapeutics’ CAR-T therapy will be added to the state-run health insurance scheme.
L impact | REGULATION | Nov 14, 2026, 03:03 AM UTC
China to Add JW Therapeutics CAR-T Therapy to State Health Insurance
China's National Healthcare Security Administration says JW Therapeutics' CAR-T therapy will be added to the state-run health insurance scheme.
M impact | REGULATION | Nov 14, 2026, 03:03 AM UTC
Trump Administration Seeks $50 Billion for Air Traffic Control After Outage
The administration boosted its request for air traffic control funding to $50 billion after a communications issue forced a nationwide groundstop, halting thousands of flights for
M impact | REGULATION | Nov 14, 2026, 02:44 AM UTC
Democratic Senators Order Musk to Preserve SpaceX Records Over Ukraine Starlink Access
The Wall Street Journal reports that Democratic senators ordered Musk to preserve SpaceX records concerning Ukraine's access to Starlink.
L impact | REGULATION | Nov 14, 2026, 12:16 AM UTC
US to End Efforts to Curb Facebook Group and App Reporting ICE Activity
A free speech nonprofit says the US will end efforts to curb a Facebook group and app that report ICE activity.
L impact | REGULATION | Nov 14, 2026, 12:06 AM UTC
Supreme Court to Review IPO Disclosure Case Involving Robinhood
Robinhood Markets won U.S. Supreme Court review in an IPO disclosure case.
M impact | REGULATION | Nov 14, 2026, 12:05 AM UTC